Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Free Cash Flow (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Free Cash Flow for 13 consecutive years, with -$47408.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 21.32% year-over-year to -$47408.0, compared with a TTM value of -$179636.0 through Nov 2025, up 15.07%, and an annual FY2025 reading of -$171305.0, up 30.21% over the prior year.
  • Free Cash Flow was -$47408.0 for Q4 2025 at CNBX Pharmaceuticals, down from -$28545.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $20517.0 in Q3 2023 and bottomed at -$702340.0 in Q1 2021.
  • Average Free Cash Flow over 5 years is -$207891.2, with a median of -$62530.5 recorded in 2023.
  • The sharpest move saw Free Cash Flow surged 113.62% in 2023, then crashed 23219.56% in 2025.
  • Year by year, Free Cash Flow stood at -$600058.0 in 2021, then surged by 84.02% to -$95915.0 in 2022, then increased by 23.85% to -$73042.0 in 2023, then soared by 46.5% to -$39077.0 in 2024, then dropped by 21.32% to -$47408.0 in 2025.
  • Business Quant data shows Free Cash Flow for CNBX at -$47408.0 in Q4 2025, -$28545.0 in Q3 2025, and -$52019.0 in Q2 2025.